Dongwha conducts phase 2 study of novel antibacterial quinolone

Dongwha Pharm says it has conducted a local phase 2 study of the oral formulation of DW-224a, a fluoroquinolone antibiotic at seven university hospitals between October 1, 2008 and October 31, 2009.

DW-224a is a newly broad-spectrum fluoroquinolone with potent activity against respiratory tract pathogens, especially Streptococcus pneumoniae. The spectrum of activity of DW-224a includes those...